Semaglutide Weight Loss: The Trial Evidence

The short version

Semaglutide weight loss is the most-studied part of this drug's record, and the headline is consistent across trials: people lose a large share of their body weight, and most of it stays off as long as they keep taking it. In the largest trial, average loss was about 15% over roughly 16 months — far more than diet-and-exercise comparison groups ^[1].

Two facts give that headline its shape. First, it lasts: two years of treatment kept the weight off ^[8]. Second, it depends on staying on the medicine — when people stopped, much of the weight came back ^[9][17]. The loss comes from eating less, because the drug quiets appetite and slows the stomach, not from burning more energy ^[4]. This page lays out the weight numbers in plain English. It is a digest of the studies, not medical advice, and it names no dose for anyone.

How much weight: the STEP 1 headline

The central semaglutide weight loss figure comes from STEP 1, a randomized trial in 1,961 adults with overweight or obesity but without diabetes. Once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68, versus -2.4% with placebo — a treatment difference of about 12.4 percentage points ^[1]. In practical terms, the average participant on treatment lost close to a seventh of their starting weight over roughly 16 months, while the comparison group lost little.

That magnitude is what set semaglutide apart from earlier weight medicines. It is an average, which means some people lost considerably more and some less; averages describe a group, not any one person. The companion STEP 2 report extended the evidence into adults who also had type 2 diabetes ^[10].

How durable: two years and the role of staying on treatment

Durability was the next question, and STEP 5 answered it: two years of once-weekly 2.4 mg produced sustained, clinically meaningful weight loss versus placebo ^[8]. The weight did not simply rebound while treatment continued.

The STEP 4 trial showed why continued treatment matters. After a 20-week run-in on semaglutide, participants were randomly assigned either to keep taking it or to switch to placebo. From week 20 to 68, those who continued lost a further 7.9% of body weight, while those switched to placebo regained 6.9% ^[9]. The medicine, in other words, has to be present to keep the effect — which reframes obesity treatment as ongoing management rather than a finite course.

What happens after stopping

The flip side of that durability is regain after discontinuation, and the evidence is candid about it. In the STEP 1 trial extension, after semaglutide was withdrawn, participants regained a mean of roughly 11.6 percentage points of body weight within one year, and the cardiometabolic improvements they had gained reverted toward baseline ^[17].

This is the single most important caveat to the weight numbers: the loss is treatment-dependent. It is consistent with how the drug works — it suppresses appetite while present, and appetite returns when it clears. Hair shedding and a more hollow-looking face, both reported during rapid weight loss, are covered as anecdotal reports on the Semaglutide effects page. The honest summary is that semaglutide produces large weight loss that persists with continued use and substantially reverses without it.

Why the weight comes off: the mechanism in brief

The weight loss is driven by reduced food intake rather than increased energy burn. In rodent studies, semaglutide reached the brainstem and the hypothalamic arcuate nucleus — brain regions that set hunger and fullness — where it activated satiety neurons and quieted hunger neurons, cutting food intake and shifting food preference, with no fall in energy expenditure ^[4]. That matches what people describe: a quieter appetite and smaller portions, summarized as anecdotal reports on the effects page. A body-composition substudy adds a caution to the weight figure — part of the weight lost is lean (muscle) mass, not only fat ^[16] — which is why protein and resistance-training research accompanies the weight-loss story. The mechanism and the broader trial set are read in full on the Semaglutide research page.